Syngene International Limited Stock Bombay S.E.
Equities
SYNGENE
INE398R01022
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
698.2 INR | -0.10% | -2.11% | -0.41% |
Sales 2024 | 34.89B 418M 572M | Sales 2025 * | 39.35B 472M 645M | Capitalization | 278B 3.33B 4.56B |
---|---|---|---|---|---|
Net income 2024 | 5.1B 61.17M 83.63M | Net income 2025 * | 5.67B 68.05M 93.04M | EV / Sales 2024 | 7.73 x |
Net cash position 2024 | 9.35B 112M 153M | Net cash position 2025 * | 9.1B 109M 149M | EV / Sales 2025 * | 6.83 x |
P/E ratio 2024 |
55.4
x | P/E ratio 2025 * |
50.9
x | Employees | 6,847 |
Yield 2024 |
0.18% | Yield 2025 * |
0.18% | Free-Float | 44.65% |
Latest transcript on Syngene International Limited
1 day | -0.10% | ||
1 week | -2.11% | ||
Current month | -0.49% | ||
1 month | -1.90% | ||
3 months | +1.78% | ||
6 months | +2.25% | ||
Current year | -0.41% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
Sibaji Biswas
DFI | Director of Finance/CFO | - | 19-12-17 |
Chairman | 71 | 94-11-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 94-11-17 | |
Director/Board Member | 67 | 17-07-30 | |
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 698.2 | -0.10% | 29,097 |
24-04-25 | 699 | +0.68% | 109,155 |
24-04-24 | 694.2 | -1.00% | 23,317 |
24-04-23 | 701.2 | -0.52% | 12,092 |
24-04-22 | 704.8 | -1.18% | 9,397 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SYNGENE Stock
- SYNGENE Stock